Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley KA, Parker JS, Singh B, Campbell JD, Ballman KV, Hillman DW, Winer EP, El-Abed S, Piccart M, Di Cosimo S, Symmans WF, Krop IE, Salgado R, Loi S, Pusztai L, Perou CM, Carey LA, Sotiriou C. Rediti M, et al. Among authors: symmans wf. Nat Commun. 2023 Nov 3;14(1):7053. doi: 10.1038/s41467-023-42635-2. Nat Commun. 2023. PMID: 37923752 Free PMC article. Clinical Trial.
Breast cancer biomarkers and molecular medicine.
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Ross JS, et al. Among authors: symmans wf. Expert Rev Mol Diagn. 2003 Sep;3(5):573-85. doi: 10.1586/14737159.3.5.573. Expert Rev Mol Diagn. 2003. PMID: 14510178 Review.
Targeted therapy in breast cancer: the HER-2/neu gene and protein.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Ross JS, et al. Among authors: symmans wf. Mol Cell Proteomics. 2004 Apr;3(4):379-98. doi: 10.1074/mcp.R400001-MCP200. Epub 2004 Feb 3. Mol Cell Proteomics. 2004. PMID: 14762215 Free article. Review.
Breast cancer biomarkers and molecular medicine: part II.
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Ross JS, et al. Among authors: symmans wf. Expert Rev Mol Diagn. 2004 Mar;4(2):169-88. doi: 10.1586/14737159.4.2.169. Expert Rev Mol Diagn. 2004. PMID: 14995904 Review.
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF. Rajan R, et al. Among authors: symmans wf. Cancer. 2004 Apr 1;100(7):1365-73. doi: 10.1002/cncr.20134. Cancer. 2004. PMID: 15042669 Free article. Clinical Trial.
294 results